Early Immunochemotherapy Timing Improves Survival in NSCLC: Phase 3 Trial Results

Patients with advanced non-small cell lung cancer (NSCLC) may benefit from having their chemoimmunotherapy administered earlier in the day, according to the results of a phase 3 randomized controlled trial published in Nature Medicine on February 2, 2026. The study, involving 210 participants, demonstrated that infusions given before 3:00 PM led to significantly improved progression-free survival (PFS) and overall survival (OS) compared to those administered later in the day.

The trial, known as LungTIME-C01 (NCT05549037), randomly assigned patients with treatment-naïve advanced NSCLC to receive chemoimmunotherapy either before 3:00 PM (early group) or at or after 3:00 PM (late group) for the first four treatment cycles. Researchers found a median PFS of 11.3 months (95% CI, 9.2-13.4 months) in the early treatment group, compared to 5.7 months (95% CI, 5.2-6.2 months) in the late treatment group (HR, 0.40. 95% CI, 0.29-0.55; P < .001). At one year, PFS rates were 47.6% (95% CI, 39.0%-58.2%) in the early group and 19.0% (95% CI, 12.8%-28.3%) in the late group.

Median overall survival was also significantly longer in the early treatment group, at 28.0 months (95% CI, not evaluable), compared to 16.8 months (95% CI, 13.7-19.9 months) in the late group (HR, 0.42; 95% CI, 0.29-0.60; P < .001). The objective response rate (ORR) was 69.5% (95% CI, 60.6%-78.5%) in the early group versus 56.2% (95% CI, 46.5%-65.8%) in the late group (P = .046).

The study authors noted that time of day of treatment administration, along with the tumor proportion score for PD-L1, were the only factors found to significantly predict both PFS and OS outcomes. “These findings have important implications for the routine clinical use of immunochemotherapy, offering a simple and cost-neutral strategy that can be readily implemented without imposing additional financial burden on the health care system,” said lead study author Zhe Huang, and coauthors in their publication.

The trial involved 210 patients with histologically or cytologically confirmed metastatic NSCLC who had not previously received treatment. Patients were excluded if they had EGFR, ALK, or ROS1 mutations. Eligible patients had an ECOG performance status of 0 or 1, a life expectancy of at least 12 weeks, and adequate bone marrow and organ function. The median age of participants was 61 years, and the majority were male (90.5% in both groups) and had a history of smoking (80.0% and 82.9% in the early and late groups, respectively).

Patients in both groups received either pembrolizumab (Keytruda) or sintilimab (Tyvyt) every three weeks until disease progression, death, or unacceptable toxicity. Chemotherapy regimens differed based on histology: patients with squamous cell carcinoma received carboplatin and nab-paclitaxel, while those with adenocarcinoma received carboplatin and pemetrexed.

The most common treatment-related adverse effects (TRAEs) of any grade were leukopenia (44.8% vs 28.6%), anemia (43.8% vs 42.9%), and thrombocytopenia (21.0%) in the early and late groups, respectively. Immune-related adverse events included rash (12.4% vs 16.2%) and hypothyroidism (11.4% vs 10.5%).

Researchers also observed differences in immune cell populations between the two groups. The early treatment group exhibited more circulating CD8⁺ T cells and a higher ratio of activated to exhausted CD8⁺ T cells, potentially explaining the improved therapy efficacy.

The findings, presented at the 2025 ASCO Annual Meeting, suggest that aligning immunochemotherapy schedules with the body’s natural circadian rhythms may offer a simple, cost-effective way to enhance standard care for NSCLC. Further research is needed to determine the long-term survival benefits and to explore whether these findings can be generalized to other cancer types and immunotherapy regimens.

References

1. Huang Z, Zeng L, Ruan Z, et al. Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial. Nat Med. Published online February 2, 2026. Doi:10.1038/s41591-025-04181-w
2. Effect of time-of-day (ToD) for immunochemotherapy on PFS in NSCLC (PACIFIC15). ClinicalTrials.gov. Updated February 19, 2025. Accessed February 3, 2026. Https://tinyurl.com/ycwraff9